Characterization and translational development of IOA-289, a novel autotaxin inhibitor for the treatment of solid tumors [0.03%]
IOA-289（一种新型自分泌运动因子抑制剂）的表征及其在实体肿瘤治疗中的转化研究
M A Deken,K Niewola-Staszkowska,O Peyruchaud et al.
M A Deken et al.
Background: Autotaxin-lysophosphatidic acid (ATX-LPA) signaling has a predominant role in immunological and fibrotic processes, including cancer. Several ATX inhibitors and LPA receptor antagonists have been clinically ev...
M Nabhan,D Egan,M Kreileder et al.
M Nabhan et al.
Immune checkpoint inhibitors (ICIs) have rejuvenated therapeutic approaches in oncology. Although responses tend to be durable, response rates vary in many cancer types. Thus, the identification and validation of predictive biomarkers is a ...
H Balke-Want,V Keerthi,A Cadinanos-Garai et al.
H Balke-Want et al.
Chimeric antigen receptor (CAR) T cell therapy has made significant strides in the treatment of B-cell malignancies, but its application in treating solid tumors still poses significant challenges. Particularly, the widespread use of viral ...
Autoantibodies involved in primary and secondary adrenal insufficiency following treatment with immune checkpoint inhibitors [0.03%]
免疫检查点抑制剂治疗后原发性和继发性肾上腺功能不全相关的自身抗体
N C Helderman,M W Lucas,C U Blank
N C Helderman
Primary and secondary adrenal insufficiency (AI) are commonly known immune-related adverse events following treatment with immune checkpoint inhibitors (ICIs), and are clinically relevant due to their morbidity and potential mortality. For ...
Á F Sanromán,K Joshi,L Au et al.
Á F Sanromán et al.
•T-cell receptor (TCR) interaction with major histocompatibility complex-antigen complexes leads to antitumour responses.•TCR sequencing analysis allows characterisation of T cells that recognise tumour neoantigens.•T-cell clonal revival...
ATMP development and pre-GMP environment in academia: a safety net for early cell and gene therapy development and manufacturing [0.03%]
学术界ATMP开发和预GMP环境：早期细胞和基因治疗开发及生产的安全网
D N Silva,M Chrobok,G Ahlén et al.
D N Silva et al.
Advanced therapy medicinal products (ATMP) are medicines for human use that are based on genes, cells or tissues. Over the past years, an increasing number of ATMP entered the market for treatment of cancer, genetic disorders, skeletal defe...
Cell Squeeze: driving more effective CD8 T-cell activation through cytosolic antigen delivery [0.03%]
细胞挤压：通过胞质抗原递送更有效地激活CD8T细胞
J C Park,H Bernstein,S Loughhead et al.
J C Park et al.
Cell Squeeze is a novel technology that relies on temporarily disrupting the cell membrane to deliver cargo directly into the cytosol. This approach is applicable to a broad range of cell types (peripheral blood mononuclear cells, red blood...
Effective generation of tumor-infiltrating lymphocyte products from metastatic non-small-cell lung cancer (NSCLC) lesions irrespective of location and previous treatments [0.03%]
来自非小细胞肺癌转移病灶的肿瘤浸润淋巴细胞产物的有效制备与其位置和既往治疗无关
S M Castenmiller,R de Groot,A Guislain et al.
S M Castenmiller et al.
Background: Non-small-cell lung cancer (NSCLC) is the leading cause of cancer-related mortality worldwide. Because current treatment regimens show limited success rates, alternative therapeutic approaches are needed. We r...